February 2009

Contents

Editorial

• Volume 10 Number 1/2 Jan/Feb 2009

Conference reports

• 9th International Congress on Drug Therapy in HIV Infection, 9-13 November 2008, Glasgow

• Summary of antiretroviral studies at Glasgow

• The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy

• Initial results from PENTA 11 trial of planned treatment interruption

• Inflammation and coagulation markers askew in children with higher HIV RNA

• Dosing of lopinavir/ritonavir in the CHIPS cohort

• Number needed to treat to harm (NNTH) analysis of impact of underlying cardiovascular factors on risk of abacavir-related heart attack

• Bone disease and HIV

• Renal tubule damage with tenofovir despite normal glomerular function

• 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 6-8 November 2008, London, UK

• Report from the 10th IWADRLH by Jacqueline Capeau

• Report from the 10th IWADRLH by Michael Dubé

• Impact of body changes on the quality of life of HIV-positive treatment-experienced patients: an online community-based survey

Antiretrovirals

• Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients

• EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naive patients in Europe

• Maraviroc safety label changes included with US traditional approval

• US approval of paediatric abacavir

• EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease

• Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA

Treatment access

• Lost benefit of ARVs in South Africa

PK and drug interactions

• Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir

• Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir

• Drug interactions with integrase inhibitors

• Drug interactions between efavirenz and itraconazole

• Effect on tacrolimus when switching from nelfinavir to fosamprenavir

Cure research

• Cause for caution on HIV cure report

Basic science and immunology

• Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption

Other news

• Martin Delaney, leading treatment activist and founder of Project Inform, dies at 63

• Report refutes HIV denialist claims on childrens HIV trials

• International AIDS Conference to be held in the US after over 20-year ban

• Changes at the European Medicines Agency (EMA)

On the web

• 39th Union World Conference on Lung Health

• Management of hepatitis B: consensus statement and data review

• PLoS medicine and PLoS clinical trials

PDFs

• Volume 10 Number 1/2 Jan/Feb 2009 PDF